LUNESTA 1 MG
ESZOPICLONE : 1 MG · DIN 02453207 · SUMITOMO PHARMA CANADA, INC.
Health Canada status: MARKETED
What is LUNESTA?
LUNESTA 1 MG contains ESZOPICLONE : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02453207, held by SUMITOMO PHARMA CANADA, INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Jan-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LUNESTA used for?
LUNESTA (eszopiclone) is indicated for short-term (usually not exceeding 7-10 days) use for: • treatment and symptomatic relief of insomnia characterized by difficulty falling asleep • frequent nocturnal awakenings and/or early morning awakenings where disturbed sleep results in impaired daytime functioning.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02453207 |
|---|---|
| Brand name | LUNESTA |
| Generic / active ingredient | ESZOPICLONE : 1 MG |
| Manufacturer | SUMITOMO PHARMA CANADA, INC. |
| Strength | 1 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05CF04 ESZOPICLONE |
| AHFS class | 28:24.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Jan-2026 |
| Original market date | 2020-10-20 00:00:00 |
How is it stored and handled?
null
How is it supplied?
The 1 mg tablets are supplied in bottles of 30 tablets. The 2 and 3 mg tablets are supplied in bottles of 100 tablets.
What can be used instead?
Other Canadian products sharing ATC code N05CF04 ESZOPICLONE. 9 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| LUNESTA | 2 MG | TABLET | SUMITOMO PHARMA CANADA, INC. | MARKETED | DIN 02453215 |
| LUNESTA | 3 MG | TABLET | SUMITOMO PHARMA CANADA, INC. | MARKETED | DIN 02453223 |
| M-ESZOPICLONE | 1 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02551187 |
| M-ESZOPICLONE | 2 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02551195 |
| M-ESZOPICLONE | 3 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02551209 |
| MAR-ESZOPICLONE | 1 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02549433 |
| MAR-ESZOPICLONE | 2 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02549441 |
| MAR-ESZOPICLONE | 3 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02549468 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.